Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
  2. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  3. Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
  4. Allergan assesses brazikumab in two clinical programmes for IBD
  5. AstraZeneca reports negative top-line results from TULIP 1 trial

Latest Content

March’s top news stories

Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients with allergic conjunctivitis.

February’s top news stories

Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.

Pulmatrix to initiate Phase II trial of Pulmazole

US-based biopharmaceutical firm Pulmatrix is set to launch a Phase II clinical trial of Pulmazole (PUR1900) in the first half of this year following receipt of approval from the US Food and Drug Administration (FDA).

January’s top news stories

Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Women’s health pipeline: profiling the GCPR target class

Health disorders in women can be caused by many abnormalities in the body and represent a very broad therapy area. Drug development for women’s health disorders has lagged behind other therapy areas, and few new therapies have been approved in the past years.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top